Lundbeck Bolsters its Parkinson’s Pipeline by Acquiring Prexton Therapeutics
By Jasmine Kalsi
Pharma Deals Review: Vol 2018 Issue 4 (Table of Contents)
Published: 11 Apr-2018
DOI: 10.3833/pdr.v2018.i4.2319 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Reinforcing its central nervous system interests, Lundbeck has signed a definitive agreement to acquire Prexton Therapeutics, a biotech that is focused on the development of novel compounds for neurodegenerative disorders...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS